Antifibrotic drugs as therapeutic tools in resistant melanoma
Melanoma is the most aggressive form of skin cancer. Together with the recent advances in immunotherapy, targeted therapy with inhibitors of the Mitogen Activated Protein Kinase (MAPKi) pathway including BRAF and MEK inhibitors has greatly improved the clinical outcome of these patients. Unfortunate...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2022-03-01
|
Series: | EMBO Molecular Medicine |
Online Access: | https://doi.org/10.15252/emmm.202115449 |